Central Nervous System Agents in Medicinal Chemistry

Central Nervous System Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5249
ISSN (Online): 1875-6166

Back Subscribe
Research Article

Study of the Antidepressant Effects of the Combination of Agmatine and Melatonin Following Restraint Stress in Mice: the Role of Oxidative Factors

Author(s): Saeed Mehrzadi, Ali Jamshidi Naeini, Fahime Azimirad and Azam Hosseinzadeh*

Volume 26, Issue 1, 2026

Published on: 25 March, 2025

Page: [95 - 102] Pages: 8

DOI: 10.2174/0118715249347833250307041355

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Objective: Major Depressive Disorder (MDD) is a psychiatric disorder that has a tight connection to stressful experiences, decreased levels of endogenous antioxidants and enhanced levels of oxidative stress. We drafted this research to define the results of combining agmatine and melatonin on stress-induced depression in mice.

Methods: Experimental groups included the non-stressed group treated with vehicle (ethanol at a concentration of 0.0005%), stressed vehicle (ethanol at a concentration of 0.0005%)-treated group, group treated with fluoxetine (10 mg/kg/day), group treated with melatonin (10 mg/kg/day), group treated with agmatine (1 mg/kg/day), group receiving a combination of melatonin (10 mg/kg/day) and agmatine (1 mg/kg/day). The animals were subjected to restraint stress for two hours daily for a duration of one week, concurrently with the daily oral administration of agents through drinking water. Open field test and forced swimming test were operated on the 8th day. The oxidative stress markers were measured in the mice hippocampus.

Results: Stress led to the elevation of immobility time. The combination group showed a significant effect in comparison to the agmatine and melatonin groups. The combination of melatonin and agmatine was successful in the elevation of hippocampus catalase activity; and this effect was comparable in the fluoxetine group. We observed enhancement of superoxide dismutase activity in treatment groups and reduction in malondialdehyde levels in melatonin, agmatine and combination groups.

Conclusion: A combination of agmatine and melatonin improves stress-induced depression more effectively than each alone, which may result from suppressing oxidative stress.

Keywords: Pharmacology, oxidative stress, melatonin, depression, agmatine, hippocampus catalase activity, hippocampus antioxidant activity.

Graphical Abstract

[1]
Yan, S.; Xu, C.; Yang, M.; Zhang, H.; Cheng, Y.; Xue, Z.; He, Z.; Wang, T.; Bai, S.; Wang, G.; Wu, J.; Tong, Z.; Cai, X. The expression of agmatinase manipulates the affective state of rats subjected to chronic restraint stress. Neuropharmacology, 2023, 229109476.
[http://dx.doi.org/10.1016/j.neuropharm.2023.109476] [PMID: 36849038]
[2]
McEwen, B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Res., 2000, 886(1-2), 172-189.
[http://dx.doi.org/10.1016/S0006-8993(00)02950-4] [PMID: 11119695]
[3]
Bathina, K.C.; ten Thij, M.; Lorenzo-Luaces, L.; Rutter, L.A.; Bollen, J. Individuals with depression express more distorted thinking on social media. Nat. Hum. Behav., 2021, 5(4), 458-466.
[http://dx.doi.org/10.1038/s41562-021-01050-7] [PMID: 33574604]
[4]
Andrade, L.; Caraveo-anduaga, J.J.; Berglund, P.; Bijl, R.V.; Graaf, R.D.; Vollebergh, W.; Dragomirecka, E.; Kohn, R.; Keller, M.; Kessler, R.C.; Kawakami, N.; Kiliç, C.; Offord, D.; Bedirhan Ustun, T.; Wittchen, H.U. The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int. J. Methods Psychiatr. Res., 2003, 12(1), 3-21.
[http://dx.doi.org/10.1002/mpr.138] [PMID: 12830306]
[5]
Al-harbi, K.S. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Prefer. Adherence, 2012, 6, 369-388.
[http://dx.doi.org/10.2147/PPA.S29716] [PMID: 22654508]
[6]
Caruso, G.; Grasso, M.; Fidilio, A.; Torrisi, S.A.; Musso, N.; Geraci, F.; Tropea, M.R.; Privitera, A.; Tascedda, F.; Puzzo, D.; Salomone, S.; Drago, F.; Leggio, G.M.; Caraci, F. Antioxidant activity of fluoxetine and vortioxetine in a non-transgenic animal model of alzheimer’s disease. Front. Pharmacol., 2021, 12809541.
[http://dx.doi.org/10.3389/fphar.2021.809541] [PMID: 35002742]
[7]
Sakhaee, E.; Ostadhadi, S.; Khan, M.I.; Yousefi, F.; Norouzi-Javidan, A.; Akbarian, R.; Chamanara, M.; Zolfaghari, S. The role of NMDA receptor and nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effect of dextromethorphan in mice forced swimming test and tail suspension test. Biomed. Pharmacother., 2017, 85, 627-634.
[http://dx.doi.org/10.1016/j.biopha.2016.11.073]
[8]
Liu, T.; Zhong, S.; Liao, X.; Chen, J.; He, T.; Lai, S.; Jia, Y. A meta-analysis of oxidative stress markers in depression. PLoS One, 2015, 10(10), e0138904.
[http://dx.doi.org/10.1371/journal.pone.0138904] [PMID: 26445247]
[9]
Mehrzadi, S.; Hosseini, A.; Hassani, S.; Azimirad, F.; Hosseinzadeh, A. Evaluating the antidepressant-like properties of melatonin and vitamin D3 combination in mice subjected to restraint stress: Investigating the involvement of Oxidative stress. Curr. Drug Ther., 2024, 19(4), 470-479.
[http://dx.doi.org/10.2174/1574885518666230811121026]
[10]
Bakunina, N.; Pariante, C.M.; Zunszain, P.A. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology, 2015, 144(3), 365-373.
[http://dx.doi.org/10.1111/imm.12443] [PMID: 25580634]
[11]
Quera Salva, M.A.; Hartley, S.; Barbot, F.; Alvarez, J.C.; Lofaso, F.; Guilleminault, C. Circadian rhythms, melatonin and depression. Curr. Pharm. Des., 2011, 17(15), 1459-1470.
[http://dx.doi.org/10.2174/138161211796197188] [PMID: 21476953]
[12]
Won, E.; Na, K.S.; Kim, Y.K. Associations between melatonin, neuroinflammation, and brain alterations in depression. Int. J. Mol. Sci., 2021, 23(1), 305.
[http://dx.doi.org/10.3390/ijms23010305] [PMID: 35008730]
[13]
Tonon, A.C.; Pilz, L.K.; Markus, R.P.; Hidalgo, M.P.; Elisabetsky, E. Melatonin and depression: A translational perspective from animal models to clinical studies. Front. Psychiatry, 2021, 12638981.
[http://dx.doi.org/10.3389/fpsyt.2021.638981] [PMID: 33897495]
[14]
Ashkenazy-Frolinger, T.; Kronfeld-Schor, N.; Juetten, J.; Einat, H. It is darkness and not light: Depression-like behaviors of diurnal unstriped Nile grass rats maintained under a short photoperiod schedule. J. Neurosci. Methods, 2010, 186(2), 165-170.
[http://dx.doi.org/10.1016/j.jneumeth.2009.11.013] [PMID: 19932714]
[15]
Dubocovich, M.L.; Markowska, M. Functional MT1 and MT2 melatonin receptors in mammals. Endocr. J., 2005, 27(2), 101-110.
[http://dx.doi.org/10.1385/ENDO:27:2:101] [PMID: 16217123]
[16]
Launay, J.M.; Lemaître, B.J.; Husson, H.P.; Dreux, C.; Hartmann, L.; Da Prada, M. Melatonin synthesis by rabbit platelets. Life Sci., 1982, 31(14), 1487-1494.
[http://dx.doi.org/10.1016/0024-3205(82)90010-8] [PMID: 7144437]
[17]
Dubocovich, M.L.; Delagrange, P.; Krause, D.N.; Sugden, D.; Cardinali, D.P.; Olcese, J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev., 2010, 62(3), 343-380.
[http://dx.doi.org/10.1124/pr.110.002832] [PMID: 20605968]
[18]
Fava, M. Daytime sleepiness and insomnia as correlates of depression. J. Clin. Psychiatry, 2004, 65(Suppl. 16), 27-32.
[PMID: 15575802]
[19]
Lam, R.W. Sleep disturbances and depression: A challenge for antidepressants. Int. Clin. Psychopharmacol., 2006, 21(Suppl. 1), S25-S29.
[http://dx.doi.org/10.1097/01.yic.0000195658.91524.61] [PMID: 16436937]
[20]
Tsuno, N.; Besset, A.; Ritchie, K. Sleep and depression. J. Clin. Psychiatry, 2005, 66(10), 1254-1269.
[http://dx.doi.org/10.4088/JCP.v66n1008] [PMID: 16259539]
[21]
Ogłodek, E.A.; Just, M.J.; Szromek, A.R.; Araszkiewicz, A. Melatonin and neurotrophins NT-3, BDNF, NGF in patients with varying levels of depression severity. Pharmacol. Rep.s, 2016, 68(5), 945.
[22]
Neis, V.B.; Bettio, L.E.B.; Moretti, M.; Rosa, P.B.; Ribeiro, C.M.; Freitas, A.E.; Gonçalves, F.M.; Leal, R.B.; Rodrigues, A.L.S. Acute agmatine administration, similar to ketamine, reverses depressive-like behavior induced by chronic unpredictable stress in mice. Pharmacol. Biochem. Behav., 2016, 150-151, 108-114.
[http://dx.doi.org/10.1016/j.pbb.2016.10.004] [PMID: 27743829]
[23]
Valverde, A.P.; Camargo, A.; Rodrigues, A.L.S. Agmatine as a novel candidate for rapid-onset antidepressant response. World J. Psychiatry, 2021, 11(11), 981-996.
[http://dx.doi.org/10.5498/wjp.v11.i11.981] [PMID: 34888168]
[24]
Feng, Y.; Piletz, J.E.; Leblanc, M.H. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr. Res., 2002, 52(4), 606-611.
[http://dx.doi.org/10.1203/00006450-200210000-00023] [PMID: 12357058]
[25]
Zhu, M.Y.; Piletz, J.E.; Halaris, A.; Regunathan, S. Effect of agmatine against cell death induced by NMDA and glutamate in neurons and PC12 cells. Cell. Mol. Neurobiol., 2003, 23(4/5), 865-872.
[http://dx.doi.org/10.1023/A:1025069407173] [PMID: 14514037]
[26]
Cai, S. Glycine/NMDA receptor antagonists as potential CNS therapeutic agents: ACEA-1021 and related compounds. Curr. Top. Med. Chem., 2006, 6(7), 651-662.
[http://dx.doi.org/10.2174/156802606776894465] [PMID: 16719807]
[27]
Huang, Z.; Huang, P.L.; Panahian, N.; Dalkara, T.; Fishman, M.C.; Moskowitz, M.A. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science, 1994, 265(5180), 1883-1885.
[http://dx.doi.org/10.1126/science.7522345] [PMID: 7522345]
[28]
Kaindl, A.M.; Degos, V.; Peineau, S.; Gouadon, E.; Chhor, V.; Loron, G.; Le Charpentier, T.; Josserand, J.; Ali, C.; Vivien, D.; Collingridge, G.L.; Lombet, A.; Issa, L.; Rene, F.; Loeffler, J.P.; Kavelaars, A.; Verney, C.; Mantz, J.; Gressens, P. Activation of microglial N‐methyl‐D‐aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Ann. Neurol., 2012, 72(4), 536-549.
[http://dx.doi.org/10.1002/ana.23626] [PMID: 23109148]
[29]
Zomkowski, A.D.E.; Hammes, L.; Lin, J.; Calixto, J.B.; Santos, A.R.S.; Rodrigues, A.L.S. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport, 2002, 13(4), 387-391.
[http://dx.doi.org/10.1097/00001756-200203250-00005] [PMID: 11930146]
[30]
Porsolt, R.D.; Bertin, A.; Jalfre, M. Behavioral despair in mice: A primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther., 1977, 229(2), 327-336.
[PMID: 596982]
[31]
Yankelevitch-Yahav, R.; Franko, M.; Huly, A.; Doron, R. The forced swim test as a model of depressive-like behavior. J. Vis. Exp., 2015, 2, 52587.
[http://dx.doi.org/10.3791/52587-v]
[32]
Borsini, F.; Meli, A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl.), 1988, 94(2), 147-160.
[http://dx.doi.org/10.1007/BF00176837] [PMID: 3127840]
[33]
Korczak, D.J.; Pereira, S.; Koulajian, K.; Matejcek, A.; Giacca, A. Type 1 diabetes mellitus and major depressive disorder: Evidence for a biological link. Diabetologia, 2011, 54(10), 2483-2493.
[http://dx.doi.org/10.1007/s00125-011-2240-3] [PMID: 21789690]
[34]
Menezes Zanoveli, J.; de Morais, H.; Caroline da Silva Dias, I.; Karoline Schreiber, A.; Pasquini de Souza, C.; Maria da Cunha, J. Depression associated with diabetes: From pathophysiology to treatment. Curr. Diabetes Rev., 2016, 12(3), 165-178.
[http://dx.doi.org/10.2174/1573399811666150515125349] [PMID: 25981499]
[35]
Rebai, R.; Jasmin, L.; Boudah, A. The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices. Brain Res. Bull., 2017, 134, 142-150.
[http://dx.doi.org/10.1016/j.brainresbull.2017.07.013] [PMID: 28746841]
[36]
Munhoz, C.D.; García-Bueno, B.; Madrigal, J.L.; Lepsch, L.B.; Scavone, C.; Leza, J.C. Stress-induced neuroinflammation: Mechanisms and new pharmacological targets. Rev. Bras. Pesqui. Med. Biol., 2008, 41(12), 1037-1046.
[37]
Jeon, S.W.; Kim, Y.K. Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness? World J. Psychiatry, 2016, 6(3), 283-293.
[http://dx.doi.org/10.5498/wjp.v6.i3.283] [PMID: 27679767]
[38]
Ali, T.; Hao, Q.; Ullah, N.; Rahman, S.U.; Shah, F.A.; He, K.; Zheng, C.; Li, W.; Murtaza, I.; Li, Y.; Jiang, Y.; Tan, Z.; Li, S. Melatonin act as an antidepressant via attenuation of neuroinflammation by targeting Sirt1/Nrf2/HO-1 signaling. Front. Mol. Neurosci., 2020, 13, 96.
[http://dx.doi.org/10.3389/fnmol.2020.00096] [PMID: 32595452]
[39]
Alcendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Tian, B.; Wagner, T.; Vatner, S.F.; Sadoshima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res., 2007, 100(10), 1512-1521.
[http://dx.doi.org/10.1161/01.RES.0000267723.65696.4a] [PMID: 17446436]
[40]
Salminen, A.; Kauppinen, A.; Suuronen, T.; Kaarniranta, K. SIRT1 longevity factor suppresses NF‐κB ‐driven immune responses: Regulation of aging via NF‐κB acetylation? BioEssays, 2008, 30(10), 939-942.
[http://dx.doi.org/10.1002/bies.20799] [PMID: 18800364]
[41]
Mohseni, G.; Ostadhadi, S.; Imran-Khan, M.; Norouzi-Javidan, A.; Zolfaghari, S.; Haddadi, N.S. Agmatine enhances the antidepressant-like effect of lithium in mouse forced swimming test through NMDA pathway. Biomed. pharmaco., 88, 931-938.2017,
[http://dx.doi.org/10.1016/j.biopha.2017.01.119]
[42]
Skolnick, P. Antidepressants for the new millennium. Eur. J. Pharmacol., 1999, 375(1-3), 31-40.
[http://dx.doi.org/10.1016/S0014-2999(99)00330-1] [PMID: 10443562]
[43]
Dias Elpo Zomkowski, A.; Oscar Rosa, A.; Lin, J.; Santos, A.R.S.; Batista Calixto, J.; Lúcia Severo Rodrigues, A. Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res., 2004, 1023(2), 253-263.
[http://dx.doi.org/10.1016/j.brainres.2004.07.041] [PMID: 15374751]
[44]
Neis, V.B.; Moretti, M.; Manosso, L.M.; Lopes, M.W.; Leal, R.B.; Rodrigues, A.L.S. Agmatine enhances antidepressant potency of MK-801 and conventional antidepressants in mice. Pharmacol. Biochem. Behav., 2015, 130, 9-14.
[http://dx.doi.org/10.1016/j.pbb.2014.12.009] [PMID: 25553821]
[45]
Taksande, B.G.; Kotagale, N.R.; Tripathi, S.J.; Ugale, R.R.; Chopde, C.T. Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology, 2009, 57(4), 415-424.
[http://dx.doi.org/10.1016/j.neuropharm.2009.06.035] [PMID: 19589348]
[46]
Bhagwagar, Z.; Wylezinska, M.; Jezzard, P.; Evans, J.; Boorman, E.; M Matthews, P.; J Cowen, P. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int. J. Neuropsychopharmacol., 2008, 11(2), 255-260.
[http://dx.doi.org/10.1017/S1461145707007924] [PMID: 17625025]
[47]
Neis, V.B.; Rosado, A.F.; Olescowicz, G.; Moretti, M.; Rosa, P.B.; Platt, N.; Rodrigues, A.L.S. The involvement of GABAergic system in the antidepressant-like effect of agmatine. Naunyn Schmiedebergs Arch. Pharmacol., 2020, 393(10), 1931-1939.
[http://dx.doi.org/10.1007/s00210-020-01910-5] [PMID: 32447465]
[48]
Freitas, A.E.; Egea, J.; Buendia, I.; Gómez-Rangel, V.; Parada, E.; Navarro, E.; Casas, A.I.; Wojnicz, A.; Ortiz, J.A.; Cuadrado, A.; Ruiz-Nuño, A.; Rodrigues, A.L.S.; Lopez, M.G. Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice. Mol. Neurobiol., 2016, 53(5), 3030-3045.
[http://dx.doi.org/10.1007/s12035-015-9182-6] [PMID: 25966970]

Rights & Permissions Print Cite